ImpriMed Unveils Cancer Treatment Prediction Technology at EHA-SfPM Meeting, Expands AI-Driven Precision Medicine Services ...
The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...
In addition to other MM indications, Isatuximab's anti-CD38 competitor on the US market, daratumumab (Darzalex — Johnson & Johnson), also carries a first-line indication for transplant-ineligible MM ...
A nurse practitioner discusses her role in caring for patients with multiple myeloma, and how advanced practice providers ...
Hosted on MSN21h
Moving mountains: Boulder woman's battle against multiple myeloma during Blood Cancer Awareness MonthA Boulder woman is opening up about her fight with multiple myeloma during Blood Cancer Awareness Month. She went from being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback